Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions
Authors
Keywords
Fatty liver, Insulin resistance, NAFLD, NASH, Non-alcoholic steatohepatitis, Pioglitazone, Prediabetes, Treatment, Type 2 diabetes
Journal
DIABETOLOGIA
Volume 59, Issue 6, Pages 1112-1120
Publisher
Springer Nature
Online
2016-04-21
DOI
10.1007/s00125-016-3952-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
- (2016) Scott Friedman et al. Contemporary Clinical Trials
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes
- (2016) L.A. Leiter et al. DIABETES & METABOLISM
- Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD
- (2016) Fernando Bril et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease
- (2015) Nishanth E. Sunny et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Adaptation of Hepatic Mitochondrial Function in Humans with Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis
- (2015) Chrysi Koliaki et al. Cell Metabolism
- Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes
- (2015) Aijaz Ahmed et al. Clinical Gastroenterology and Hepatology
- Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
- (2015) Sunder Mudaliar et al. DIABETES CARE
- Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
- (2015) Yuka Hayashizaki-Someya et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- (2015) Paul Angulo et al. GASTROENTEROLOGY
- Time to Abandon NASH?
- (2015) Jean-François Dufour HEPATOLOGY
- Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study
- (2015) Edith M. Koehler et al. HEPATOLOGY
- High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population?
- (2015) Aijaz Ahmed et al. HEPATOLOGY
- Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study
- (2015) Lisa B. VanWagner et al. HEPATOLOGY
- Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009
- (2015) Zobair M. Younossi et al. HEPATOLOGY
- Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)
- (2015) Rohit Loomba et al. HEPATOLOGY
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
- (2015) James D. Lewis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Vildagliptin on Hepatic Steatosis
- (2015) Mavin Macauley et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
- (2015) Paola Portillo-Sanchez et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis
- (2015) Srinivasan Dasarathy et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver
- (2015) Santhosh Satapati et al. JOURNAL OF CLINICAL INVESTIGATION
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients
- (2015) Fernando Bril et al. LIVER INTERNATIONAL
- Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats
- (2015) R. J. Perry et al. SCIENCE
- Practice patterns in NAFLD and NASH: real life differs from published guidelines
- (2015) Mary E. Rinella et al. Therapeutic Advances in Gastroenterology
- Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes
- (2014) Raymond E. Soccio et al. Cell Metabolism
- The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
- (2014) Rifaat Safadi et al. Clinical Gastroenterology and Hepatology
- GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes
- (2014) Bertrand Cariou et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets
- (2014) Ffolliott M. Fisher et al. GASTROENTEROLOGY
- The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease
- (2014) Maryann Maximos et al. HEPATOLOGY
- Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
- (2014) Changtao Jiang et al. JOURNAL OF CLINICAL INVESTIGATION
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial
- (2014) Norbert Stefan et al. Lancet Diabetes & Endocrinology
- Cohort Study of Non-alcoholic Fatty Liver Disease, NAFLD fibrosis score and the Risk of Incident Diabetes in a Korean population
- (2013) Yoosoo Chang et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
- (2013) Hanford Yau et al. Current Diabetes Reports
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
- (2013) F. J. Lavalle-González et al. DIABETOLOGIA
- Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches
- (2013) Romina Lomonaco et al. DRUGS
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease
- (2013) Karima Begriche et al. HEPATOLOGY
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis
- (2013) Fernando Bril et al. HEPATOLOGY
- Extrahepatic complications of nonalcoholic fatty liver disease
- (2013) Matthew J. Armstrong et al. HEPATOLOGY
- A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
- (2013) Raluca Pais et al. JOURNAL OF HEPATOLOGY
- Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
- (2013) Peter G. Traber et al. PLoS One
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
- (2012) Kenneth Cusi GASTROENTEROLOGY
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
- (2012) Naga Chalasani et al. GASTROENTEROLOGY
- Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial
- (2012) Thuy-Anh Le et al. HEPATOLOGY
- A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease
- (2012) Stephen P. Casey et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Excessive Hepatic Mitochondrial TCA Cycle and Gluconeogenesis in Humans with Nonalcoholic Fatty Liver Disease
- (2011) Nishanth E. Sunny et al. Cell Metabolism
- Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
- (2011) Tomoyuki Iwasaki et al. HEPATO-GASTROENTEROLOGY
- Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis
- (2011) Romina Lomonaco et al. HEPATOLOGY
- Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
- (2011) Claudia O. Zein et al. HEPATOLOGY
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents
- (2011) Joel E. Lavine JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Vitamin E and the Risk of Prostate Cancer
- (2011) Eric A. Klein et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
- (2011) Gianluca Svegliati-Baroni et al. LIVER INTERNATIONAL
- Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors
- (2011) Nathalie C. Leite et al. LIVER INTERNATIONAL
- Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
- (2011) Ralph A. DeFronzo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pioglitazone in the treatment of NASH: the role of adiponectin
- (2010) A. Gastaldelli et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites
- (2010) Brent A. Neuschwander-Tetri HEPATOLOGY
- Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease
- (2010) Elisa Fabbrini et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
- (2010) Renata Belfort et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus
- (2010) Nathalie C. Leite et al. LIVER INTERNATIONAL
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis
- (2009) Amalia Gastaldelli et al. HEPATOLOGY
- A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis
- (2009) Austin Nelson et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
- (2008) R. LOOMBA et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
- (2008) Justin I. Odegaard et al. Cell Metabolism
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started